Joint Symptoms and Disorder

You have full text access to this OnlineOpen article

Association between the use of serotonin receptor 2A–blocking antidepressants and joint disorders

  1. Anders Kling1,*,
  2. Marit Danell-Boman1,
  3. Hans Stenlund2,
  4. Rune Dahlqvist1

Article first published online: 29 SEP 2009

DOI: 10.1002/art.24673

Issue

Arthritis Care & Research

Arthritis Care & Research

Volume 61, Issue 10, pages 1322–1327, 15 October 2009

Additional Information

How to Cite

Kling, A., Danell-Boman, M., Stenlund, H. and Dahlqvist, R. (2009), Association between the use of serotonin receptor 2A–blocking antidepressants and joint disorders. Arthritis & Rheumatism, 61: 1322–1327. doi: 10.1002/art.24673

Author Information

  1. 1

    University Hospital, Umeå, Sweden

  2. 2

    Umeå University, Umeå, Sweden

*Division of Clinical Pharmacology, University Hospital, SE-901 85 Umeå, Sweden

Publication History

  1. Issue published online: 29 SEP 2009
  2. Article first published online: 29 SEP 2009
  3. Manuscript Accepted: 18 MAY 2009
  4. Manuscript Received: 17 DEC 2008

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (75K)

REFERENCES

  • 1
    Maksymowych WP, Jhangri GS, Fitzgerald AA, LeClercq S, Chiu P, Yan A, et al. A six-month randomized, controlled, double-blind, dose-response comparison of intravenous pamidronate (60 mg versus 10 mg) in the treatment of nonsteroidal antiinflammatory drug–refractory ankylosing spondylitis. Arthritis Rheum 2002; 46: 766–73.
    Direct Link:
  • 2
    Bock O, Boerst H, Thomasius FE, Degner C, Stephan-Oelkers M, Valentine SM, et al. Common musculoskeletal adverse effects of oral treatment with once weekly alendronate and risedronate in patients with osteoporosis and ways for their prevention. J Musculoskelet Neuronal Interact 2007; 7: 144–8.
  • 3
    Hoyer D, Hannon JP, Martin GR. Molecular, pharmacological and functional diversity of 5-HT receptors. Pharmacol Biochem Behav 2002; 71: 533–54.
  • 4
    Stefulj J, Jernej B, Cicin-Sain L, Rinner I, Schauenstein K. mRNA expression of serotonin receptors in cells of the immune tissues of the rat. Brain Behav Immun 2000; 14: 219–24.
  • 5
    Leon-Ponte M, Ahern GP, O'Connell PJ. Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood 2007; 109: 3139–46.
  • 6
    Hood SD, Argyropoulos SV, Nutt DJ. Arthritis and serotonergic antidepressants. J Clin Psychopharmacol 2001; 21: 458–61.
  • 7
    Jolliet P, Veyrac G, Bourin M. First report of mirtazapine-induced arthralgia. Eur Psychiatry 2001; 16: 503–5.
  • 8
    Ostensen M, Myhr K. Mianserin as a cause of arthritis [letter]. Br J Rheumatol 1991; 30: 74–5.
  • 9
    Passier A, van Puijenbroek E. Mirtazapine-induced arthralgia. Br J Clin Pharmacol 2005; 60: 570–2.
    Direct Link:
  • 10
    Marie I, Delafenetre H, Massy N, Thuillez C, Noblet C, and the Network of the French Pharmacovigilance Centers. Tendinous disorders attributed to statins: a study on ninety-six spontaneous reports in the period 1990–2005 and review of the literature. Arthritis Rheum 2008; 59: 367–72.
    Direct Link:
  • 11
    Uppsala Monitoring Centre. WHO programme for international drug monitoring. 2008. URL: http://www.who-umc.org/DynPage.aspx?id=13140&mn=1514#1.
  • 12
    Bate A. Bayesian confidence propagation neural network. Drug Saf 2007; 30: 623–5.
  • 13
    World Health Organization. International monitoring of adverse reactions to drugs: adverse reaction terminology. Uppsala (Sweden): WHO Collaborating Centre for International Drug Monitoring; 2003.
  • 14
    Läkemedelsverkets Klassificeringssystem. Uppsala (Sweden): MPA; 2009.
  • 15
    World Health Organization Collaborating Centre for Drug Statistics Methodology, Norwegian Institute of Public Health. About the ATC/DDD system. 2004. URL: http://www.whocc.no/atcddd/atcsystem.html.
  • 16
    Uppsala Monitoring Centre. Reporting to the WHO database. 2009. URL: http://www.who-umc.org/DynPage.aspx?id=13140&mn=1514#6.
  • 17
    Hazell L, Shakir SA. Under-reporting of adverse drug reactions: a systematic review. Drug Saf 2006; 29: 385–96.
  • 18
    Kling A, Rantapaa-Dahlqvist S, Stenlund H, Mjorndal T. Decreased density of serotonin 5-HT2A receptors in rheumatoid arthritis. Ann Rheum Dis 2006; 65: 816–9.
  • 19
    Kling A, Seddighzadeh M, Arlestig L, Alfredsson L, Rantapaa-Dahlqvist S, Padyukov L. Genetic variations in the serotonin 5-HT2A receptor gene (HTR2A) are associated with rheumatoid arthritis. Ann Rheum Dis 2008; 67: 1111–5.
  • 20
    Polesskaya OO, Sokolov BP. Differential expression of the “C” and “T” alleles of the 5-HT2A receptor gene in the temporal cortex of normal individuals and schizophrenics. J Neurosci Res 2002; 67: 812–22.
    Direct Link:
  • 21
    Guillet-Deniau I, Burnol AF, Girard J. Identification and localization of a skeletal muscle secrotonin 5-HT2A receptor coupled to the Jak/STAT pathway. J Biol Chem 1997; 272: 14825–9.
  • 22
    Pierce PA, Xie GX, Peroutka SJ, Green PG, Levine JD. 5-Hydroxytryptamine-induced synovial plasma extravasation is mediated via 5-hydroxytryptamine2A receptors on sympathetic efferent terminals. J Pharmacol Exp Ther 1995; 275: 502–8.
  • 23
    Toth M, Shenk T. Antagonist-mediated down-regulation of 5-hydroxytryptamine type 2 receptor gene expression: modulation of transcription. Mol Pharmacol 1994; 45: 1095–100.
View Full Article (HTML) Get PDF (75K)